Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revacept in Stable CAD Undergoing PCI
NCT03312855Phase 2Completed
- Sponsor
- Deutsches Herzzentrum München
- Start
- Nov 2017
- Primary completion
- Feb 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of revacept in coronary artery disease (CAD), sponsored by Deutsches Herzzentrum München. Started Nov 2017; status: completed.
02
Drugs
revacept
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03312855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03312855.